Population Group – Talk Bio

Aerska; Irish biotech; RNA interference (RNAi); brain shuttles; blood-brain barrier; neurological diseases; Alzheimer’s; Parkinson’s; gene silencing; precision medicine; antibody-oligonucleotide conjugates

Enanta Presses Ahead with RSV Drug Zelicapavir Despite Missing Primary Endpoint in Phase IIb Trial

4 weeks ago talkbio0Tagged Clinical Trials, Congestive heart failure, COPD, development aspects, Elderly (population group), Enanta, Hospitalization, Neoplasm Metastasis, Phase II B Trial, primary endpoint, rates, Respiratory syncytial virus, United States Food and Drug Administration, Zelicapavir

Enanta Pharmaceuticals; RSV; zelicapavir; Phase IIb trial; primary endpoint miss; secondary endpoints; clinical trials; FDA Fast Track; elderly; COPD; congestive heart failure; hospitalization rates; future development

CDC Staff and Medical Organization Liaisons Barred from New ACIP Covid-19 Working Group

2 months ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), COVID19 (disease), Jr., medical groups, Policy, Robert F. Kennedy, staff exclusion, Vaccines, Working Group

CDC; ACIP; Covid-19; working group; staff exclusion; medical groups barred; vaccine policy; Robert F. Kennedy Jr.

Uncertainty Clouds Finances for Payers and Health Systems in Q2 2025

2 months ago talkbio0Tagged Budgets, Changing, Consumer, federal, health systems, healthcare financial performance, Hospital admission, Medicaid, Medicare, payers, Policy, Q2 2025, Uncertainty

Q2 2025; healthcare financial performance; payers; health systems; uncertainty; Medicaid; Medicare; admissions; policy changes; federal budget; consumer confidence

FDA restricts bluebird bio’s Skysona to CALD patients without suitable stem cell donors after higher blood cancer risk emerges

3 months ago talkbio0Tagged boxed, CALD, Cautionary Warning, Cerebral Adrenoleukodystrophy, Donor person, Elivaldogene autotemcel, gene therapy, Hematologic Neoplasms, HLA Match, label update, Leukemia, Myelocytic, Acute, MYELODYSPLASTIC SYNDROME, Safety, Skysona, United States Food and Drug Administration

FDA; bluebird bio; Skysona; elivaldogene autotemcel; eli-cel; cerebral adrenoleukodystrophy; CALD; hematologic malignancies; myelodysplastic syndrome (MDS); acute myeloid leukemia (AML); boxed warning; label update; postmarketing safety; HLA-matched donor; gene therapy safety

Y-mAbs Therapeutics Acquired by SERB Pharmaceuticals in $412 Million Buyout Following Strategic Review

3 months ago talkbio0Tagged all-cash tender, Danyelza, Infrequent, Merger, Neoplasms, pharmaceutical acquisition, Serbs, strategic review, Y-mAbs

Y-mAbs Therapeutics; SERB Pharmaceuticals; buyout; Danyelza; rare oncology; merger; pharmaceutical acquisition; strategic review; all-cash tender offer

Trump’s Pharmaceutical Tariffs Materialize in New US-EU Trade Deal

3 months ago talkbio0Tagged 15%, European (ethnic group), Evaluation, pharmaceutical tariffs, Sectioning technique, tariff, trade agreement, Transplant Registry Unified Management Program, U.S., Union, US-EU

Trump; pharmaceutical tariffs; US-EU trade deal; 15% tariff; Section 232 investigation; European Union exports; trade agreement